Search

Your search keyword '"Hagen, Melissa B."' showing total 5 results
Start Over Author "Hagen, Melissa B."
5 results on '"Hagen, Melissa B."'

1. The Trajectory of Antibody Responses One Year Following SARS-CoV-2 Infection among Indigenous Individuals in the Southwest United States.

Author

Smith, Claire P., Hartman, Rachel M., Kugler, Alexa M., Little, Verlena, Baker, Owen R., Fairlie, Tarayn A., Fernandez, Reinaldo E., Hagen, Melissa B., Honie, Elvira, Laeyendecker, Oliver, Midgley, Claire M., Parker, Dennie, Sandoval, Marqia, Takahashi, Saki, Hammitt, Laura L., and Sutcliffe, Catherine G.

Subjects
ANTIBODY formation, INDIGENOUS peoples, SARS-CoV-2, IMMUNITY, ADULTS
Abstract

SARS-CoV-2 antibody kinetics based on immunologic history is not fully understood. We analyzed anti-spike and anti-nucleocapsid antibody responses following acute infection in a cohort of Indigenous persons. The models of peak concentrations and decay rates estimated that one year after infection, participants would serorevert for anti-nucleocapsid antibodies and remain seropositive for anti-spike antibodies. The peak anti-spike concentrations were higher for individuals vaccinated prior to infection, but the decay rates were similar across immunologic status groups. Children had significantly lower peak anti-spike concentrations than adults. This study affirms the importance of continued vaccination to maintain high levels of immunity in the face of waning immunity. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

2. Acquired HIV drug resistance and virologic monitoring in a HIV hyper-endemic setting in KwaZulu-Natal Province, South Africa

Author

Chimukangara, Benjamin, Lessells, Richard J., Singh, Lavanya, Grigalionyte, Indra, Yende-Zuma, Nonhlanhla, Adams, Rochelle, Dawood, Halima, Dlamini, Linda, Buthelezi, Sibonisile, Chetty, Sheldon, Diallo, Karidia, Duffus, Wayne A., Mogashoa, Mary, Hagen, Melissa B., Giandhari, Jennifer, de Oliveira, Tulio, Moodley, Pravi, Padayatchi, Nesri, and Naidoo, Kogieleum

Published
2021
Full Text
View/download PDF

3. Antigen Test Positivity After COVID-19 Isolation--Yukon-Kuskokwim Delta Region, Alaska, January-February 2022

Author

Lefferts, Brian, Blake, Ian, Bruden, Dana, Hagen, Melissa B., Hodges, Ellen, Kirking, Hannah L., Bates, Elizabeth, Hoeldt, Amanda, Lamont, Brenda, Saydah, Sharon, MacNeil, Adam, Bruce, Michael G., and Plumb, Ian D.

Subjects
Antigens -- Health aspects, Infection -- Health aspects, Health
Abstract

Isolation is recommended during acute infection with SARS-CoV-2, the virus that causes COVID-19, but the duration of infectiousness varies among individual persons. Rapid antigen test results have been correlated with [...]

Published
2022

4. Additional file 1 of Acquired HIV drug resistance and virologic monitoring in a HIV hyper-endemic setting in KwaZulu-Natal Province, South Africa

Author

Chimukangara, Benjamin, Lessells, Richard J., Singh, Lavanya, Grigalionyte, Indra, Yende-Zuma, Nonhlanhla, Adams, Rochelle, Dawood, Halima, Dlamini, Linda, Buthelezi, Sibonisile, Chetty, Sheldon, Diallo, Karidia, Duffus, Wayne A., Mogashoa, Mary, Hagen, Melissa B., Giandhari, Jennifer, de Oliveira, Tulio, Moodley, Pravi, Padayatchi, Nesri, and Naidoo, Kogieleum

Subjects
parasitic diseases
Abstract

Additional file 1: Figure S1. Study flow diagram from participant selection to reporting of results in the acquired HIV drug resistance study in KwaZulu-Natal (KZN) province, South Africa, May–September 2019. Table S1. Comparison of participant characteristics among samples excluded and included in final analysis in the acquired HIV drug resistance study in KwaZulu-Natal (KZN) province, South Africa, May–September 2019. Table S2. Patterns of drug class resistance among participants on first- and second-line ART in the acquired HIV drug resistance study in KwaZulu-Natal (KZN) province, South Africa, May–September 2019. Table S3. Prevalence of specific acquired drug resistance mutations in the acquired HIV drug resistance study in KwaZulu-Natal (KZN) province, South Africa, May–September 2019. Table S4. Relationship between patient characteristics and acquired drug resistance using multivariable logistic regression.

Published
2021
Full Text
View/download PDF

5. Antigen Test Positivity After COVID-19 Isolation - Yukon-Kuskokwim Delta Region, Alaska, January-February 2022.

Author

Lefferts B, Blake I, Bruden D, Hagen MB, Hodges E, Kirking HL, Bates E, Hoeldt A, Lamont B, Saydah S, MacNeil A, Bruce MG, and Plumb ID

Subjects
Adolescent, Adult, Alaska epidemiology, Alaska Natives, COVID-19 prevention & control, COVID-19 transmission, Child, Child, Preschool, Female, Health Planning Guidelines, Humans, Infant, Male, Middle Aged, Young Adult, COVID-19 diagnosis, COVID-19 Serological Testing, Quarantine, SARS-CoV-2
Abstract

Isolation is recommended during acute infection with SARS-CoV-2, the virus that causes COVID-19, but the duration of infectiousness varies among individual persons. Rapid antigen test results have been correlated with detection of viable virus (1-3) and might inform isolation guidance, but data are limited for the recently emerged SARS-CoV-2 B.1.1.529 (Omicron) variant. On January 5, 2022, the Yukon-Kuskokwim Health Corporation (YKHC) recommended that persons with SARS-CoV-2 infection isolate for 10 days after symptom onset (or, for asymptomatic persons, 10 days after a positive nucleic acid amplification or antigen test result). However, isolation could end after 5-9 days if symptoms were resolving or absent, fever was absent for ≥24 hours without fever-reducing medications, and an Abbott BinaxNOW COVID-19 Ag (BinaxNOW) rapid antigen test result was negative. Antigen test results and associated individual characteristics were analyzed among 3,502 infections reported to YKHC during January 1-February 9, 2022. After 5-9 days, 396 of 729 persons evaluated (54.3%) had a positive antigen test result, with a declining percentage positive over time. In a multivariable model, a positive antigen test result was more likely after 5 days compared with 9 days (adjusted odds ratio [aOR] = 6.39) or after symptomatic infection (aOR = 9.63), and less likely after previous infection (aOR = 0.30), receipt of a primary COVID-19 vaccination series (aOR = 0.60), or after both previous infection and receipt of a primary COVID-19 vaccination series (aOR = 0.17). Antigen tests might be a useful tool to guide recommendations for isolation after SARS-CoV-2 infection. During the 10 days after infection, persons might be infectious to others and are recommended to wear a well-fitting mask when around others, even if ending isolation after 5 days., Competing Interests: All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results